BurkDiff: a real-time PCR allelic discriminiation assay for Burkholderia pseudomallei and B. mallei by Bowers, Jolene R. et al.
BurkDiff: A Real-Time PCR Allelic Discrimination Assay for
Burkholderia Pseudomallei and B. mallei
Jolene R. Bowers1*, David M. Engelthaler1, Jennifer L. Ginther2, Talima Pearson2, Sharon J. Peacock3,
Apichai Tuanyok2, David M. Wagner2, Bart J. Currie4, Paul S. Keim1,2
1 Translational Genomics Research Institute, Flagstaff, Arizona, United States of America, 2Northern Arizona University, Flagstaff, Arizona, United States of America,
3Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand, 4Menzies School of Health Research, Darwin,
Australia
Abstract
A real-time PCR assay, BurkDiff, was designed to target a unique conserved region in the B. pseudomallei and B. mallei
genomes containing a SNP that differentiates the two species. Sensitivity and specificity were assessed by screening
BurkDiff across 469 isolates of B. pseudomallei, 49 isolates of B. mallei, and 390 isolates of clinically relevant non-target
species. Concordance of results with traditional speciation methods and no cross-reactivity to non-target species show
BurkDiff is a robust, highly validated assay for the detection and differentiation of B. pseudomallei and B. mallei.
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Introduction
The bacterial species Burkholderia pseudomallei and B. mallei,
though genetically very similar, have divergent lifestyles. B.
pseudomallei is a soil saprophyte and facultative pathogen and the
cause of melioidosis, while B. mallei is an obligate pathogen and the
cause of glanders. Melioidosis is mostly a disease of humans and
animals in Southeast Asia and Northern Australia, where B.
pseudomallei is present in the environment; infection mainly results
from percutaneous inoculation or inhalation or aspiration of the
organism. Clinical manifestations of melioidosis can be asymp-
tomatic, localized to virtually any organ, or disseminated, though
the primary presentations are pneumonia and sepsis, where
mortality rates are significant [1,2]. Glanders is mainly an equine
disease found in much of the world, except for North America,
Europe and Australia, with transmission to humans occurring
primarily through direct contact with animals and aerosols [3,4].
Clinical manifestations of glanders in humans are similar to those
of melioidosis [1,5]. Both species of bacteria cause fast-progressing
diseases and both are intrinsically resistant to several antibiotics.
As such, the rapid detection and identification of these species is
essential for immediate appropriate patient therapy. Both species
are also potential bioterrorism agents, deemed by the U.S. Centers
for Disease Control and Prevention Category B Select Agents [6],
for which no human vaccine is available. In this context, rapid
differentiation of melioidosis and human glanders is paramount for
epidemiological surveillance and forensic investigation.
Identification of B. pseudomallei and B. mallei and the diagnosis of
melioidosis and glanders currently depend on time-consuming
culture of the organism. Confirmation by biochemical assays can
add a week onto definitive species identification [1]. Rapid
biochemical assays have resulted in misdiagnosis of melioidosis, a
mistake not easily detected due to the myriad clinical manifesta-
tions of the disease, and the lack of vigilance for these organisms in
non-endemic regions [7,8]. Serologic assays can be erroneous [8],
are contingent on a delayed immune response, and are useful
really only in non-endemic areas, where seroconversion due to
previous exposure is improbable [1]. Antigen-specific assays,
including direct immunofluorescent microscopy [9] and latex
agglutination [10], have proven to be rapid and sensitive, but are
not as yet available commercially.
Molecular methods to identify B. pseudomallei and B. mallei now
exist that utilize various platforms: Sanger sequencing [11],
multiplex PCR [12], real-time PCR [13,14,15,16], and isothermal
DNA amplification [17]. Several of these assays show promise as
rapid alternatives to biochemical tests; however few have been
extensively validated for robustness and specificity. B. pseudomallei
and B. mallei are relatively genetically promiscuous, making
development of robust, specific single-locus assay diagnostics
challenging [18,19].
A single-reaction real-time PCR Taqman allelic discrimination
assay was previously developed to identify and differentiate B.
pseudomallei and B. mallei [20]. Further analysis of this assay against
larger strain collections revealed some false positive identification:
a strain of B. oklahomensis types as B. pseudomallei, and the B.
thailandensis-like strain MSMB43 types as B. mallei (unpublished
data).
Here we introduce a new more highly validated allelic
discrimination assay, referred to as BurkDiff, to provide a higher
level of specificity for accurate identification of B. pseudomallei and B.
mallei and simultaneous differentiation when necessary. Alternative-
ly, as these two species often occupy disparate niches under normal
circumstances, BurkDiff can be used as a single-probe assay for
definitive identification of B. pseudomallei or B. mallei.
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e15413
Table 1. Number and origin of B. pseudomallei, B. mallei, and genetic near-neighbor strains used in this study.
Species Country Isolated from No. of isolates TaqMan result (SNP state)
B. mallei China Human 2 C
China Animal 4 C
China Unknown 2 C
France Unknown 1 C
Hungary Animal 1 C
Hungary Unknown 1 C
India Animal 3 C
India Unknown 1 C
Pakistan Unknown 6 C
Turkey Human 4 C
Turkey Animal 1 C
Turkey Unknown 10 C
UK Unknown 1 C
USA Human 4 C
USA Animal 1 C
USA Unknown 3 C
Unknown Animal 2 C
Unknown Unknown 2 C
Total 8 49
B. pseudomallei Australia Human 131 A
Australia Animal 10 A
Australia Environmental 57 A
Australia Unknown 6 A
Bangladesh Human 2 A
Cambodia Unknown 2 A
China Unknown 3 A
Ecuador Human 2 A
Ecuador Animal 1 A
Fiji Human 1 A
India Unknown 1 A
Indonesia Environmental 1 A
Kenya Human 1 A
Kenya Environmental 2 A
Laos Unknown 2 A
Madagascar Environmental 2 A
Malaysia Human 2 A
Malaysia Environmental 3 A
Malaysia Unknown 15 A
Mauritius Human 1 A
Pakistan Human 2 A
Papua New Guinea Human 1 A
Papua New Guinea Unknown 1 A
Puerto Rico Human 2 A
Singapore Human 2 A
Singapore Environmental 1 A
Sweden Human 1 A
Thailand Human 89 A
Thailand Environmental 105 A
Unknown Human 1 A
Unknown Environmental 2 A
A Real-Time PCR Assay for Burkholderia sp.
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Methods
We used the methods described by Pearson et al. [21] to compare
23 B. pseudomallei and 10 B. mallei genomes to search for shared
orthologous SNPs, then filtered them by mismatch value (the
distance to the next SNP in bases). We further analyzed the resultant
pool of SNPs and their flanking regions with a GenBank BLAST
search, and finally chose one for assay development and validation.
Using Primer Express 3.0 software (Life Technologies, Foster
City, CA), we designed a Taqman SNP dual-probe allelic dis-
crimination assay in which one probe was designed to hybridize
with the B. mallei allele (59-FAM-CTGAAACGCGCAGCG-39-
MGB) and the other to the B. pseudomallei allele (59-VIC-CT-
GAAACGCGAAGCG-39-MGB). Real-time PCR was carried out
in 10 uL reactions containing 900 nM of both forward (59-
CGAGCGCATCGTACTCGTA-39) and reverse (59- CAAGT-
CGTGGATGCGCATTA-39) primers, 200 nM of each probe,
1X Applied Biosystems Genotyping Mastermix, and 0.5 ng
template. Thermal cycling and endpoint analysis was performed
on an AB 7900HT sequence detection system (Life Technologies)
using the following conditions: 50uC for 2 min, 95uC for 10 min,
and 40 cycles of 95uC for 15 s and 58uC for 1 min.
To evaluate the utility of this SNP and its locus as a diagnostic
marker for B. pseudomallei and B. mallei, we used the Taqman allelic
discrimination assay to genotype a collection of human, animal,
and environmental isolates of B. pseudomallei (n = 469) and B. mallei
(n = 49) from a broad geographic range (Table 1). Additionally we
assessed specificity by screening isolates of near-neighbor species
(n = 62), and isolates of species of similar clinical presentation or
normal flora (n = 328) (Table 2). All isolates were originally
identified by standard microbiological techniques in the laboratory
of origin.
The limit of detection of the Taqman assay was assessed using a
dilution series of DNA from isolates of B. pseudomallei and B. mallei.
DNA was quantified using an in-house 16S real-time qPCR assay
(unpublished). Template amounts ranging from 106 to 100 genome
copies per reaction were used for limit of detection determination.
Results
Genome comparisons revealed 1,235 SNPs with shared
character states among all B. mallei genomes that differ from the
character state shared by all B. pseudomallei genomes. Filtering the
1,235 SNPs using a mismatch value of 100 resulted in a pool of 74
SNPs. The GenBank BLAST search revealed the exclusivity of
one of the regions to B. pseudomallei and B. mallei, so it was selected
for assay development and validation.
Out of the isolates screened with BurkDiff, all 469 B. pseudomallei
strains were shown to contain the allele with the SNP state A, and
all 49 B. mallei strains were shown to contain that with the SNP
state C (Table 1, Figure 1). No amplification of DNA from the 390
non-target species was detected, including the B. oklahomensis and
the B. thailandensis-like strain MSMB43, both of which cross-
reacted with a previously published allelic discrimination assay
[20]. The limit of detection analysis showed consistent detection
and allelic discrimination of B. pseudomallei and B. mallei at DNA
template levels as low as 102 genome copies with sporadic
amplification and genotyping at ,102 genome copies (Figure 2).
Discussion
The universality of the clinical manifestations of humanmelioidosis
and glanders precludes patient presentation as a definitive diagnostic
for these diseases [3,22]. Diagnosis by traditional methods can be too
time-consuming, or require special equipment [1]. The intrinsic
resistance of B. pseudomallei and B. mallei to many widely-used
antibiotics and the swift downward progression of untreated or
inappropriately-treated B. pseudomallei- and B. mallei-infected patients
necessitate the rapid, specific identification of these species in the
clinic [1,3]. The likelihood of infection with B. pseudomallei and B.
mallei may not be equal given the circumstances; factors such as
geographical distribution, prevalence, and risk factors for the diseases
would be used in clinical practice for diagnosis. However there are
scenarios in which the two species’ distinction is necessary. The trade
restrictions imposed when animal glanders is diagnosed, but not
animal melioidosis, and the potential use of B. pseudomallei or B. mallei
as a bioterrorism agent both underscore the need to differentiate
between the two species for reporting purposes and forensic tracking
[22,23]. Rapid species identification may assist with appropriate
initial patient treatment for human glanders. Currently physicians
prescribe the lengthy drug regimen particular for melioidosis to
human glanders patients [3], despite the differing in vitro antibiotic
susceptibility profiles of the two causative agents [24]. Of the rapid
molecular methodologies with the capabilities of identifying and
differentiating between B. pseudomallei and B. mallei, BurkDiff is unique
in being single-step, single-reaction. In cases in which circumstances
eliminate the possibility of one of the two species, BurkDiff can be
used as a single-probe assay for specific identification.
Species Country Isolated from No. of isolates TaqMan result (SNP state)
Unknown Unknown 2 A
USA Human 6 A
Venezuela Human 1 A
Vietnam Human 4 A
Vietnam Animal 1 A
Vietnam Unknown 3 A
Total 22 469
B. cepacia USA 2 Negative
B. oklahomensis USA 2 Negative




A Real-Time PCR Assay for Burkholderia sp.
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The increasingly cosmopolitan nature of human activity inevitably
exposes non-endemic area residents to B. pseudomallei and B. mallei,
increasing the need for heightened awareness of these organisms
outside their areas of endemicity, as has been demonstrated by
numerous cases of imported melioidosis [25,26]. Most of these cases
can be attributed to exposure during travel to tropical areas.
However, global trade in commodities such as animals, plants and
soils, and food items is also a possible transmission source resulting in
disease in individuals with no travel history [27]. Diagnostic
capabilities in non-endemic areas are becoming essential, not only
for rapid, appropriate patient treatment, but for the safety of
laboratory workers culturing the unknown organism for diagnosis
Table 2. Species and number of differential diagnostic and background flora strains screened across BurkDiff to validate the
assay’s specificity.
Species No. of strains Species No. of strains
Abiotrophia/Granulicatella grp 1 Neisseria gonorrhoeae 4
Achromobacter xylosoxidans 1 Neisseria meningitidis 3
Acinetobacter baumanni 7 Pasteurella multocida 1
Bacillus anthracis 1 Propionibacterium sp. 1
Bacillus cereus 1 Providencia stuartii 1
Bacillus sp. 2 Pseudomonas aeruginosa 7
Bacteroides fragilis 1 Rhizopus oryzae 1
Bacteroides uniformis 1 Rothia mucilaginosa 1
Bordetella bronchiseptica 1 Salmonella enterica 1
Brucella abortus 1 Shigella dysenteriae 1
Brucella suis 1 Staphylococcus arlettae 1
Candida albicans 5 Staphylococcus aureus 55
Candida glabrata 2 Staphylococcus capitis 1
Candida parapsilosis 3 Staphylococcus cohnii 1
Candida tropicalis 1 Staphylococcus epidermidis 8
Chryseobacterium indologenes 1 Staphylococcus equorum 1
Coagulase negative Staphylococcus 16 Staphylococcus gallinarum 1
Coccidioides immitis 1 Staphylococcus haemolyticus 3
Coccidioides posadasii 2 Staphylococcus hominis 1
Corynebacterium diphtheriae 1 Staphylococcus kloosii 1
Corynebacterium jeikeium 1 Staphylococcus lugdunensis 1
Coxiella burnetii 2 Staphylococcus saprophyticus 2
Enterobacter aerogenes 2 Staphylococcus xylosus 3
Enterobacter cloacae 10 Stenotrophomonas maltophilia 1
Enterococcus faecalis 9 Streptococcus agalactiae 9
Enterococcus faecium 6 Streptococcus anginosus 2
Escherichia coli 11 Streptococcus equi 1
Francisella tularensis 2 Streptococcus gordonii 1
Haemophilus influenzae 4 Streptococcus mitis 2
Haemophilus parainfluenzae 2 Streptococcus mutans 1
Human gDNA 2 Streptococcus oralis 1
Klebsiella oxytoca 1 Streptococcus pneumoniae 56
Klebsiella pneumoniae 8 Streptococcus pyogenes 13
Lactococcus lactis 1 Streptococcus salivarius 2
Legionella pneumophila 1 Streptococcus thermophilus 1
Listeria monocytogenes 1 Streptococcus uberis 1
Micrococcus sp. 1 Streptococcus viridans grp 8
Moraxella catarrhalis 7 Vancomycin Resistant Enterococcus 4
Mycobacterium avium 1 Yersinia pestis 1
Mycoplasma pneumoniae 1 Yersinia pseudotuberculosis 1
Total 328
Out of the 328 strains from approximately 80 species, none amplified.
doi:10.1371/journal.pone.0015413.t002
A Real-Time PCR Assay for Burkholderia sp.
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[26]. Molecular assays, including BurkDiff, are rapid, sensitive, and
specific, requiring only the appropriate thermal cycler and reagents
common to many labs and obviating the need for direct culture of a
dangerous pathogen. In fact, BurkDiff was successfully used among a
panel of real-time assays targeting B. pseudomallei in the confirmation
and characterization of a melioidosis case in an Arizona resident with
no travel history [27].
Our use of whole genome sequence data allowed for targeted
identification of phylogenetically informative markers (i.e., SNPs)
to distinguish between B. pseudomallei and B. mallei, a preferred
method to random identification of SNPs in conserved genes, as
was done previously [20]. Additionally, in silico analyses of the
markers allowed for the design of a highly specific assay. The
illustrated specificity of BurkDiff to B. pseudomallei and B. mallei
suggests that insertion of the genomic region that this assay targets
occurred during or subsequent to the B. pseudomallei/B. mallei
evolutionary split from its close genetic relative B. thailandensis [28].
Our data also suggest that the SNP targeted by BurkDiff is from a
subsequent point mutation that occurred after the B. mallei lineage
diverged from B. pseudomallei [28]. The number and diversity of the
B. pseudomallei and B. mallei isolates successfully genotyped using
BurkDiff suggest the genomic insertion is evolutionarily stable and
Figure 1. BurkDiff allelic discrimination plot. Results from the assay across 45 B. pseudomallei and 23 B. mallei strains are shown, along with 2
no template controls (NTCs) and 26 near-neighbor and differential diagnostic species.
doi:10.1371/journal.pone.0015413.g001
A Real-Time PCR Assay for Burkholderia sp.
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therefore a good target for identifying the species, while the point
mutation could now be considered a canonical SNP (canSNP), a
point mutation that marks a point of evolutionary divergence of
two taxa and is inherently stable and thus definitive [29].
BurkDiff adds to the growing number of molecular based assays,
especially real-time PCR, that have been designed to detect B.
pseudomallei and/or B. mallei. Using several of these assays in
combination for definitive identification could be important, as the
Burkholderiaceae are highly recombining organisms [15,19,30],
and as more and more strains are uncovered, the robustness and
sensitivity of these assays will be challenged.
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